



Nicast To Exhibit and Present Results of the AVflo™ Clinical
Trial at the Charing Cross 31st International Symposium in London

Nicast plans to begin post marketing clinical studies in Europe in 2009

Lod, Israel, March 12, 2009 --- Nicast, developer of medical devices made of electrospun nanofabric, announced today that it will exhibit the AVflo™ vascular access graft for hemodialysis, its flagship product which received CE certification in October 2008, at the Charing Cross 31st International Symposium in London, April 4-7, 2009, booth number 154.

During the conference, Professor S Mandika Wijeyaratne, MBBS MS MD (Leeds) FRCS (Eng), Professor in Surgery, University of Colombo, Consultant Vascular & Transplant Surgeon, National Hospital Colombo, Sri Lanka and the PI of the AVFlo clinical study, will address participants on the topic "Safety and efficacy of a new polycarbonate-urethane graft for early vascular access in end stage renal disease: First clinical results in man". The presentation will take place on Sunday, April 5th at 16:50 at the CX "New Technology Dragon's Den" Learning Center 3. Professor Wijeyaratne will also be available during the conference at Nicast's booth to answer any questions.

AVflo is a self-sealing vascular access graft that enables unobstructed blood flow, allows for dialysis within 24-48 hours after implantation and self-seals within less than five minutes following withdrawal of the dialysis needles. It is simple to implant and to suture to blood vessels; the needle punctures and suture holes self-seal rapidly. AVflo is also strong enough to withstand the pressure of blood flow, yet thin enough for blood flow to be easily felt through it.

"This is an exciting time for Nicast as we are transitioning from a pre-sales company to a revenue generating company. We already have sales of AVflo in Europe and South East Asia, and we are expanding our network of select distributors in key countries. Nicast is also planning to commence in the near future a post marketing multi-site clinical study of AVflo in Europe," said Mr. Benjamin Eliason, CEO of Nicast.

"The medical community has been quite impressed with Nicast's electrospinning technology and products. We are enjoying an unprecedented level of interest in pursuing joint projects, a topic we are always open to discussing," said Dr. Jacob Dagan, chairman of the board of Nicast.

Details of the studies will be released in a future communication.



About Nicast Ltd.

Nicast Ltd. is a pioneer in the development of superior implantable medical devices made of electrospun polymer nanofabrics for a wide range of applications. The company is currently focused on the development and marketing of the AVflo vascular access graft and the NovaMesh ventral hernia mesh, which address a combined global market of \$0.7 billion to \$1 billion. Headquartered in Lod, Israel, Nicast has six patents in the U.S., ten patents outside of the U.S. and 14 additional patents pending. For more information please visit the company's web site at www.nicast.com. To schedule an interview with chairman of the board Dr. Jacob Dagan or CEO Mr. Benjamin Eliason, please contact Marjie Hadad, media liaison, at +972-54-536-5220 or at marjie@netvision.net.il.